Navigation Links
Life Technologies Launches Ion AmpliSeq™ Custom Panels, Unlocking Thousands of Disease-Related Research Samples for Analysis

CARLSBAD, Calif., March 27, 2012 /PRNewswire/ -- Life Technologies Corporation (NASDAQ: LIFE) today launched Ion AmpliSeq™ Custom Panels that will transform disease research by unlocking hundreds of thousands of precious archived research samples containing low amounts of DNA from repositories around the globe. The highest multiplexed PCR-based solution on the market with a one-day workflow, Ion AmpliSeq™ Custom Panels require only 10 ng of input DNA and 3.5 hours for library construction - 100 times less DNA and twice as fast as other technologies. Ion AmpliSeq™ Designer, a new online application, also enables scientists to easily design and order the panels for the world's fastest-selling benchtop sequencer – the Ion Personal Genome Machine (PGM™).

"We are at a tipping point in genetics, particularly in cancer research," said Dr. Jonathan M. Rothberg, Founder and CEO of Ion Torrent. "With Ion AmpliSeq Custom Panels, scientists can analyze all their genes of interest in a single day using only 10 ng of input DNA.  No other available technology can match this level of speed and simplicity. Custom AmpliSeq enables discovery of key driver mutations in oncology samples and offers a path for use beyond research laboratories."

The Ion AmpliSeq technology enables custom targeted resequencing from samples with very low amounts of DNA such as formalin fixed paraffin embedded (FFPE) tissue. This gives scientists the flexibility to analyze mutations in tens to hundreds of genes implicated in many different disease states, more simply and economically than ever before.

Ion AmpliSeq™ Designer extensively leverages Life Technologies' TaqMan® assay design pipeline to create optimized gene panels.  Panels can be designed in as little as 2.5 hours for regions up to 250 Kb in size, expanding to 1 Mb later in 2012, and may contain up to 1,536 amplicons per reaction.  Ion Torrent's intuitive data analysis methods enable rapid scaling from analyzing just a few genes to hundreds of genes – all in a single day.

Ion AmpliSeq™ Designer builds upon the well-received Ion AmpliSeq™ Cancer Panel, which has accelerated cancer research for scientists like Dr. Sean Grimmond, Professor at the Queensland Centre for Medical Genomics. Dr. Grimmond said: "We have been using custom AmpliSeq as a means to rapid screen the prevalence of mutations in a series of novel pancreatic cancer genes we have found through exome sequencing as part of the International Cancer Genome Consortium. AmpliSeq is an excellent validating tool in cancer genome studies due to its speed, minimal template requirements and its overall robustness."

Watch an introduction and an in-depth explanation of the Ion AmpliSeq™ Custom Panels and the Ion AmpliSeq™ Designer. For more information, visit

The above referenced products are for Research Use Only. Not intended for human diagnostics purposes.

About Life Technologies

Life Technologies Corporation (NASDAQ: LIFE) is a global biotechnology company with customers in more than 160 countries using its innovative solutions to solve some of today's most difficult scientific challenges. Quality and innovation are accessible to every lab with its reliable and easy-to-use solutions spanning the biological spectrum with more than 50,000 products for translational research, molecular medicine and diagnostics, stem cell-based therapies, forensics, food safety and animal health. Its systems, reagents and consumables represent some of the most cited brands in scientific research including: Ion Torrent™, Applied Biosystems®,  Invitrogen™, GIBCO®, Ambion®, Molecular Probes®, Novex®, and TaqMan®. Life Technologies employs approximately 10,400 people and upholds its ongoing commitment to innovation with more than 4,000 patents and exclusive licenses. LIFE had sales of $3.7 billion in 2011. Visit us at our website:

Life Technologies' Safe Harbor Statement

This press release includes forward-looking statements about our anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies' plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words "believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and the like, and/or future tense or conditional constructions ("will," "may," "could," "should," etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.


Life Technologies Contact
Mauricio Minotta


SOURCE Life Technologies
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Wound Management Technologies Names Robert Lutz, Jr. as New CEO; Buys Back North American Distribution Rights for CellerateRX® Powder
2. Frost & Sullivans Advanced Medical Technologies Research Tracks Opportunities in Markets Influenced by Dynamic Care Pathways
3. Antibody Drugs: Technologies and Global Markets
4. Novation Releases Its Latest Transcatheter Cardiovascular Therapeutics Report to Help Members Understand and Prepare for New Technologies
5. OriGene Technologies Announces the Release Specificity-Verified UltraMAB™ Antibodies
6. Blue Belt Technologies to Showcase Navio™ PFS System at CAOS UK 2012 Conference in Glasgow, UK
7. Life Technologies Launches GeneArt® Precision TALs
8. BioStorage Technologies to Host Live Webinar on Optimizing the Value of Sample Assets
9. PLC Announces Ministry of Health Approval to Distribute RenalGuard® in Israel Through A.M.I. Technologies, Ltd.
10. Omnicell to Exhibit at Dubai International Pharmaceuticals and Technologies Conference and Exhibition
11. Palatin Technologies Completes Enrollment in Phase 2B Bremelanotide Female Sexual Dysfunction Trial
Post Your Comments:
(Date:6/23/2016)... 2016  In a startling report released today, National Safety ... lacking a comprehensive, proven plan to eliminate prescription opioid overdoses. ... how states are tackling the worst drug crisis in recorded U.S. ... Kentucky , New Mexico , ... Of the 28 failing states, three – Michigan ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Key Pharma News Issue 52" report to their offering. ... need in influenza treatment creates a favourable commercial environment for ... and growing patient base that will serve to drive considerable ... flu vaccine would serve to cap sales considerably, but development ...
(Date:6/23/2016)... BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia ... the company,s second affiliate in Latin America . ... ... Farma Colombia ... ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... was developed to enhance the health of felines. The formula is all-natural and is ... herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus ...
(Date:6/25/2016)... Austin, TX (PRWEB) , ... June 25, 2016 , ... ... Fellow of the American College of Mohs Surgery and to Dr. Russell Peckham for ... popular and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, ... and his M.D from the David Geffen School of Medicine at UCLA. He trained ... Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June ... with. The article goes on to state that individuals are now more comfortable seeking ... common operations such as calf and cheek reduction. The Los Angeles area medical group, ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... and Scientific Sessions in Dallas that it will receive two significant new grants ... grants came as PHA marked its 25th anniversary by recognizing patients, medical professionals ...
Breaking Medicine News(10 mins):